Castle biosciences inc.

Castle Biosciences is a pioneer in this field of spatial biology. Our biologically aware AI platform delivered Tissue Cypher® to the clinic, the world’s first precision medicine test to predict the risk of developing esophageal cancer in Barrett’s Esophagus patients – one of the world’s deadliest cancers.

Castle biosciences inc. Things To Know About Castle biosciences inc.

Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences Third Quarter 2023 Conference Call. As a reminder, today’s call is being recorded. We will begin today’s call with opening remarks and introductions, followed by a question-and-answer …Castle Biosciences Inc (CSTL) USD0.001 ; Trade low · $19.59 ; Year low · $9.26 ; Previous · $0.13 ; Volume · n/a ; Dividend yield · 0.00%.Castle Biosciences Inc’s price is currently up 22.54% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $19.70 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26.October 19, 2021 07:00 AM Eastern Daylight Time. FRIENDSWOOD, Texas-- ( BUSINESS WIRE )--Castle Biosciences, Inc. (Nasdaq: CSTL), applying innovative diagnostics to transform disease management ...

Castle Biosciences, Inc. 19.85. +0.47. +2.43%. Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences ...THIS EXECUTIVE EMPLOYMENT AGREEMENT (this “Agreement”) is entered into as of September 15, 2008 (the “Effective Date”) by and between Castle Biosciences, Inc., a Delaware corporation (the “Company”), and Kristen Oelschlager (“Executive”) (collectively referred to as the “Parties” or individually referred to as a “Party”).

Castle Biosciences, Inc. is a commercial-stage diagnostics company. The Company is focused on providing physicians and their patients with personalized, clinically actionable information to clinicians and their patients to inform treatment decisions and improve health outcomes. Castle Biosciences is a commercial stage dermatological cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more ...

A Focus on Transforming Disease Management. Our approach to product development starts by identifying areas of unmet medical need where precision medicine could significantly improve disease staging and/or patient care decisions. We focus first on confirming the clinical challenges of these unmet needs and look for opportunities where current ...Castle Biosciences Inc (NASDAQ:CSTL) reported a 66% increase in Q3 2023 revenue over Q3 2022, reaching $61 million. Total test reports increased by 52% over Q3 2022.Castle Biosciences, Inc. (CSTL) CEO Derek Maetzold on Q1 2022 Results - Earnings Call Transcript. SA Transcripts Mon, May 09, 2022.Tracfone Wireless Inc has been a leading player in the telecommunications industry, offering innovative solutions and cutting-edge technology to its customers. With a focus on providing reliable and affordable wireless services, Tracfone ha...3 Castle Biosciences, Inc, Friendswood, Texas. 4 University of Rochester, Rochester, New York. 5 Icahn School of Medicine at Mount Sinai, New York, New York; Arkansas Dermatology Skin Cancer Center, Little Rock, Arkansas. 6 Oregon Health & Science University, Portland, Oregon.

Apr 26, 2022 · FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has completed its ...

Castle Biosciences, Inc. is heading to Philadelphia for the upcoming IMPSG Symposium on November 9 from 1-7 PM. Join us for a presentation by Matt… Liked by Alyssa Benavidez

Age : 54. Public asset : 2,021,277 USD. Linked companies : Castle Biosciences, Inc. Summary. Kristen M. Oelschlager is Chief Operating Officer for Castle Biosciences, Inc. Ms. Oelschlager previously held the position of Clinical Research Coordinator at Maricopa County Special Health Care District (Arizona).CASTLE BIOSCIENCES INC: Street Address 1 Street Address 2; 2014 SAN MIGUEL DR: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; FRIENDSWOOD: TEXAS: 77546: 281-796-9032: 3. Related Persons. Last Name First Name Middle Name; Maetzold: Derek: Street Address 1 Street Address 2; c/o Castle Biosciences, Inc.Apr 4, 2022 · Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced it has signed a definitive agreement to acquire AltheaDx, Inc. (AltheaDx). AltheaDx is a commercial-stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx) testing services that ... Aug 2, 2023 · CASTLE BIOSCIENCES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (in thousands) Six Months Ended. June 30, 2023 2022 OPERATING ACTIVITIES Net loss $ (47,981 ) $ ... Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) ...

Castle Biosciences, Inc is an Affirmative Action and Equal Opportunity Employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, sex, sexual orientation, gender identity, national origin, or protected veteran status and will not be discriminated against on the basis of disability.Castle Biosciences, Inc. | 10,098 followers on LinkedIn. Improving health through innovative tests that guide patient care | Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company...Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ...Order a test. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.Age : 60. Public asset : 93,771 USD. Linked companies : Thermo Fisher Scientific Inc. - Castle Biosciences, Inc. Summary. Kimberlee S. Caple is on the board of Castle Biosciences, Inc. and Vice President & GM-Genetic Science Business at Thermo Fisher Scientific, Inc. In the past Ms. Caple held the position of VP & GM-Molecular Diagnostics ...Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive ...

Castle Biosciences is a pioneer in this field of spatial biology. Our biologically aware AI platform delivered Tissue Cypher® to the clinic, the world’s first precision medicine test to predict the risk of developing esophageal cancer in Barrett’s Esophagus patients – one of the world’s deadliest cancers. Castle Biosciences continues to pursue deployment …White Castle does not allow for the purchase of franchises. Each of the restaurants is privately owned and operated through the White Castle parent company. Because the company is privately owned, it doesn’t offer stock options to the publi...

C/O CASTLE BIOSCIENCES, INC. 505 S. FRIENDSWOOD DRIVE, SUITE 401 (Street) FRIENDSWOOD: TX: 77546 (City) (State) (Zip) 2. Issuer Name and Ticker or Trading Symbol CASTLE BIOSCIENCES INC [ CSTL] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X: Director:Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Conference Call November 2, 2023 4:30 PM ET. Company Participants. Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs.Castle Biosciences (NASDAQ:CSTL) has a recorded net income of -$67.14 million. CSTL has generated -$2.84 earnings per share over the last four quarters. What is Castle Biosciences's EPS forecast for next year? Castle Biosciences's earnings are expected to grow from ($3.15) per share to ($3.00) per share in the next year.The following unaudited pro forma condensed combined financial information was prepared to give effect to the transaction between Castle Biosciences, Inc. (“Castle” or the “Company”) and Cernostics, Inc., Inc. (“Cernostics”) pursuant to an Agreement and Plan of Merger dated October 18, 2021, as amended (the “Merger Agreement”).Board Chairman. Daniel M. Bradbury has served as a member our board of directors since September 2012, and as chairman of our board of directors since September 2014. Mr. Bradbury is co-founder and Executive Chairman of Equillium, Inc., a publicly traded biotechnology company, where he also served as its CEO from June 2018 until January 2020 ...FRIENDSWOOD, Texas, March 10, 2023--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that new ...View a summary page of this 2022 CONTRACT to CASTLE BIOSCIENCES, INC. from the Department of Veterans Affairs.Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma ... Acquisition will expand Castle’s estimated U.S. TAM by approximately $1 billion Castle executive management to host conference call and webcast today at 7:30 a.m. ET FRIENDSWOOD, Texas--(BUSINESS WIRE)—Oct. 19, 2021-- Castle Biosciences, Inc. (Nasdaq: CSTL), applying innovative diagnostics to transform disease management and …

Nov 14, 2023 · Castle Biosciences Inc’s price is currently up 22.54% so far this month. During the month of November, Castle Biosciences Inc’s stock price has reached a high of $19.70 and a low of $15.28. Over the last year, Castle Biosciences Inc has hit prices as high as $29.59 and as low as $9.26.

Age : 54. Public asset : 2,021,277 USD. Linked companies : Castle Biosciences, Inc. Summary. Kristen M. Oelschlager is Chief Operating Officer for Castle Biosciences, Inc. Ms. Oelschlager previously held the position of Clinical Research Coordinator at Maricopa County Special Health Care District (Arizona).

If you're a new customer to Castle Biosciences, please call us when ordering a test. If a returning customer, you can use the requisition form. Skip to content. COVID-19 Response. Customer Service: 866-788-9007. CLINICIAN PORTAL. ORDER TEST. COVID-19 Response. ORDER TEST. Customer Service: 866-788-9007.Overview. Castle Biosciences is improving health through our innovative tests that guide patient care. For the diseases that our portfolio of tests cover, we believe the traditional approach to developing a treatment plan for cancers and other diseases using clinical and pathology factors alone is inadequate and can be improved by incorporating the personalized information our tests provide.23 May 2023 ... Castle Biosciences Inc., which uses spatial biology and artificial intelligence driven-image analysis, will use the Nova Place lab for analyzing ...Christopher Ballas is Chief Technology Officer at Castle Creek Biosciences, Inc. He has over 25 years of experience with cell and gene therapies in academic and industry roles covering research, development, testing, and manufacturing of viral vectors and cell therapies. Dr. Ballas recently was the Sr. Vice President of Manufacturing for Innovative …Nov 3, 2022 · Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs Deciding the frequency and intensity of follow-up and surveillance. DecisionDx-SCC is performed on formalin-fixed, paraffin embedded (FFPE) primary tumor tissue from either a biopsy or excision. Castle Biosciences is a molecular diagnostics company that provides tumor-specific information for improved treatment decisions and patient outcomes.Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2023 Earnings Call Transcript November 3, 2023 Operator: Good afternoon and welcome to Castle Biosciences Third Quarter 2023 Conference Call. As a reminder, today’s call is being recorded. We will begin today’s call with opening remarks and introductions, followed by a question-and-answer …Castle Biosciences, Inc. (NASDAQ:CSTL) Q2 2023 Earnings Call Transcript Cathie Wood's Top 15 Small-Cap Stock Picks Small Caps Begin to Rebound: 5 Stocks to …Nov 3, 2022 · Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2022 Earnings Conference Call November 2, 2022 4:30 PM ET Company Participants Camilla Zuckero - Vice President, Investor Relations and Corporate Affairs Castle Biosciences, Inc. (Exact name of registrant as specified in its charter) ...

You are cordially invited to attend the 2021 annual meeting of stockholders (the “Annual Meeting”) of Castle Biosciences, Inc., a Delaware corporation (the “Company”). The Annual Meeting will be held on Thursday, June 10, 2021, at 11:00 a.m. (local time) at the San Luis Resort, Spa and Conference Center, 5222 Seawall Boulevard ... An experienced team with deep expertise in discovering, developing, and commercializing diagnostic and prognostic tests. Castle Biosciences offers diagnostic tests that provide actionable, tumor-specific information for improved treatment decisions and patient outcomes. 2022 Annual Report April 12, 2023 2022 Annual Report. 2022 Proxy Statement April 21, 2022 2022 Proxy Statement. 2021 Annual Report April 21, 2022 2021 Annual Report. 2021 Proxy Supplement May 13, 2021 2021 Proxy Supplement. 2021 Proxy Statement April 27, 2021 2021 Proxy Statement.you invested in castle biosciences, inc. and it’s time to vote! this is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on may 25, 2023 at 10:00 a.m. edt at the omni william penn hotel, 530 william penn place, pittsburgh, pennsylvania 15219. ...Instagram:https://instagram. amway stockamericanelectricpowernovember 2023 soybean futureslv sands stock FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will share new ...Castle Biosciences, Inc. (CSTL) Q3 2023 Earnings Call Transcript SA Transcripts Fri, Nov. 03 Castle Biosciences GAAP EPS of -$0.26 beats by $0.50, revenue of $61.5M beats by $12.94M how to find iphone when on silentprice of roku stock Castle Biosciences (Nasdaq: CSTL) is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information ...What happened. Castle Biosciences ( CSTL -0.50%) stock was absolutely crushing it on Friday, with shares skyrocketing 54.4% as of 11:47 a.m. ET. The huge gain came after Novitas, a regional ... janus henderson enterprise fund FRIENDSWOOD, Texas--(BUSINESS WIRE)--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that the Centers for ...Nov 2, 2023 · Castle Biosciences, Inc., a company improving health through innovative tests that guide patient care, today announced its financial results for the third quarter and nine months ended September ... The average Castle Biosciences, Inc. salary ranges from approximately $39,729 per year for Administrative Assistant to $106,781 per year for IT Engineer. Salary information comes from 20 data points collected directly from employees, users, and past and present job advertisements on Indeed in the past 36 months.